drugset / Trial / NCT01631318

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

NCT01631318

NaSingle-groupOpen-labelDiagnostic

Summary

Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases

Timeline

Start
2012-11-01
Primary completion
2020-08-31
Completion
2020-09-30

Drugs

EvaluationDrugModalityDoseRoute
Background Definity Diagnostic / imaging agent 0.4 ml Intravenous